Healthcare / Drug Manufacturers - Specialty & GenericKSE
$3670.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $62.2B · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$253.9B
P/E
4.4x
↓EV/EBITDA
2.6x
↓ROE
21.9%
↑Gross Margin
50.7%
↑Debt/Equity
1.35
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.9%
FCF CAGR
+47.0%
FCF margin
11.2%
FCF / Net income
1.86x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $969.57B · net income $58.50B · FCF $108.97B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $969.57B | $969.57B | $887.71B | $928.07B | $864.54B |
| Net Income | $58.50B | $58.50B | $62.62B | $19.03B | $22.15B |
| EBITDA | $207.75B | $207.75B | $231.39B | $130.14B | $136.41B |
| EPS | 841.00 | 841.00 | 874.00 | 265.00 | 306.49 |
| Gross Margin | 50.7% | 50.7% | 49.0% | 48.1% | 46.3% |
| Operating Margin | 17.3% | 17.3% | 16.5% | 15.7% | 13.1% |
| Net Margin | 6.0% | 6.0% | 7.1% | 2.1% | 2.6% |
| Balance Sheet | |||||
| Debt/Equity | 1.35 | 1.35 | 1.90 | 4.47 | 5.16 |
| Current Ratio | 0.73 | 0.73 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $108.97B | $108.97B | $62.19B | $27.01B | $34.32B |
| Returns | |||||
| ROE | 21.9% | 21.9% | 27.3% | 15.3% | 20.7% |
| Valuation | |||||
| P/E | 4.36 | 4.36 | 3.46 | 12.68 | 9.05 |
| EV/EBITDA | 2.61 | 2.61 | 2.63 | 5.55 | 5.07 |
| P/B | 0.96 | 0.96 | 0.94 | 1.95 | 1.87 |
| Growth & Yield | |||||
| Revenue Growth | 9.2% | 9.2% | -4.3% | 7.3% | — |
| EPS Growth | -3.8% | -3.8% | 229.8% | -13.5% | — |
| Dividend Yield | 5.9% | 5.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-27.1%
EPS terminal req.
$325.65
Spread vs growth
23.3%
5Y implied EPS CAGR
-14.1%
EPS terminal req.
$394.04
Spread vs growth
10.3%
10Y implied EPS CAGR
-2.8%
EPS terminal req.
$634.60
Spread vs growth
-1.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+24.4%
Start / end P/E
3.5x → 4.4x
EPS bridge
874.00 → 841.00
Residual
-0.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.